Abingworth is an investment firm dedicated to the life sciences sector on both sides of the Atlantic. The company invests across all stages of development, including early-stage as well as public companies. Abingworth has provided backing for more than 100 unquoted life science businesses.

Over 70% of these have gone public or have merged or been acquired. Abingworth has funds under management of more than $1.25 billion. Founded in 1973, Abingworth has offices in London, Cambridge (UK), Menlo Park (California) and Boston.

Abingworth's funds are exclusively dedicated to life sciences.

Abingworth's team has a strong scientific background in addition to business, financial and other specialist skills. These include legal, investment banking, fund-raising as well as operating and recruiting capabilities. These resources are extended to portfolio companies in order to help build successful companies.

Abingworth's team offering is further complimented by a network of scientific and industry consultants who contribute to the process of evaluating new opportunities, creating companies and supporting existing portfolio investments.

This combination of broad-ranging experience and resources enables Abingworth to assist companies at any stage of development, including during and after the IPO process.

Abingworth seeks to invest in the best opportunities in the life sciences market. Investments have been made in platform and enabling technologies, devices and instrumentation as well as in companies developing products in a range of therapeutic areas.

Abingworth's investments are based in the US and Europe including the UK, Belgium, Denmark, France, Germany, Holland and Sweden.

Abingworth's investments range from £7.5 million up to £20 million per investment after all private rounds of financing.